69 related articles for article (PubMed ID: 14693549)
1. The interferon inducer ampligen [poly(I)-poly(C12U)] markedly protects mice against coxsackie B3 virus-induced myocarditis.
Padalko E; Nuyens D; De Palma A; Verbeken E; Aerts JL; De Clercq E; Carmeliet P; Neyts J
Antimicrob Agents Chemother; 2004 Jan; 48(1):267-74. PubMed ID: 14693549
[TBL] [Abstract][Full Text] [Related]
2. Mismatched double-stranded RNA: polyI:polyC12U.
Adis Editorial
Drugs R D; 2004; 5(5):297-304. PubMed ID: 15357629
[TBL] [Abstract][Full Text] [Related]
3. Tissue-specific deletion of the coxsackievirus and adenovirus receptor protects mice from virus-induced pancreatitis and myocarditis.
Kallewaard NL; Zhang L; Chen JW; Guttenberg M; Sanchez MD; Bergelson JM
Cell Host Microbe; 2009 Jul; 6(1):91-8. PubMed ID: 19616768
[TBL] [Abstract][Full Text] [Related]
4. Toll-like receptor agonists as cancer vaccine adjuvants.
Jeon D; Hill E; McNeel DG
Hum Vaccin Immunother; 2024 Dec; 20(1):2297453. PubMed ID: 38155525
[TBL] [Abstract][Full Text] [Related]
5. TLR Agonists as Mediators of Trained Immunity: Mechanistic Insight and Immunotherapeutic Potential to Combat Infection.
Owen AM; Fults JB; Patil NK; Hernandez A; Bohannon JK
Front Immunol; 2020; 11():622614. PubMed ID: 33679711
[TBL] [Abstract][Full Text] [Related]
6. Emerging Technologies for the Treatment of COVID-19.
Aghamollaei H; Sarvestani R; Bakherad H; Zare H; Guest PC; Ranjbar R; Sahebkar A
Adv Exp Med Biol; 2021; 1321():81-96. PubMed ID: 33656715
[TBL] [Abstract][Full Text] [Related]
7. Status presens of antiviral drugs and strategies: Part II: RNA VIRUSES (EXCEPT RETROVIRUSES).
De Clercq E
Adv Antivir Drug Des; 2007; 5():59-112. PubMed ID: 32288473
[TBL] [Abstract][Full Text] [Related]
8. Enterovirus 71 targets the cardiopulmonary system in a robust oral infection mouse model.
Chang CS; Liao CC; Liou AT; Chang YS; Chang YT; Tzeng BH; Chen CC; Shih C
Sci Rep; 2019 Jul; 9(1):11108. PubMed ID: 31366973
[TBL] [Abstract][Full Text] [Related]
9. Over-expression of mitochondrial antiviral signaling protein inhibits coxsackievirus B3 infection by enhancing type-I interferons production.
Zhang QM; Song WQ; Li YJ; Qian J; Zhai AX; Wu J; Li AM; He JM; Zhao JY; Yu X; Wei LL; Zhang FM
Virol J; 2012 Dec; 9():312. PubMed ID: 23249700
[TBL] [Abstract][Full Text] [Related]
10. Protective role of Toll-like Receptor 3-induced type I interferon in murine coronavirus infection of macrophages.
Mazaleuskaya L; Veltrop R; Ikpeze N; Martin-Garcia J; Navas-Martin S
Viruses; 2012 May; 4(5):901-23. PubMed ID: 22754655
[TBL] [Abstract][Full Text] [Related]
11. Highlights in antiviral drug research: antivirals at the horizon.
De Clercq E
Med Res Rev; 2013 Nov; 33(6):1215-48. PubMed ID: 22553111
[TBL] [Abstract][Full Text] [Related]
12. Oral administration of interferon-α2b-transformed Bifidobacterium longum protects BALB/c mice against coxsackievirus B3-induced myocarditis.
Yu Z; Huang Z; Shao C; Huang Y; Zhang F; Yang J; Deng L; Zeng Z; Deng Q; Zeng W
Virol J; 2011 Dec; 8():525. PubMed ID: 22151967
[TBL] [Abstract][Full Text] [Related]
13. Antiviral effects of interferon-β are enhanced in the absence of the translational suppressor 4E-BP1 in myocarditis induced by Coxsackievirus B3.
Burke JD; Sonenberg N; Platanias LC; Fish EN
Antivir Ther; 2011; 16(4):577-84. PubMed ID: 21685545
[TBL] [Abstract][Full Text] [Related]
14. A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo.
Day CW; Baric R; Cai SX; Frieman M; Kumaki Y; Morrey JD; Smee DF; Barnard DL
Virology; 2009 Dec; 395(2):210-22. PubMed ID: 19853271
[TBL] [Abstract][Full Text] [Related]
15. Predicting the sensitivity and specificity of published real-time PCR assays.
Lemmon GH; Gardner SN
Ann Clin Microbiol Antimicrob; 2008 Sep; 7():18. PubMed ID: 18817537
[TBL] [Abstract][Full Text] [Related]
16. The thiazolobenzimidazole TBZE-029 inhibits enterovirus replication by targeting a short region immediately downstream from motif C in the nonstructural protein 2C.
De Palma AM; Heggermont W; Lanke K; Coutard B; Bergmann M; Monforte AM; Canard B; De Clercq E; Chimirri A; Pürstinger G; Rohayem J; van Kuppeveld F; Neyts J
J Virol; 2008 May; 82(10):4720-30. PubMed ID: 18337578
[TBL] [Abstract][Full Text] [Related]
17. Interferon and its inducers--a never-ending story: "old" and "new" data in a new perspective.
De Clercq E
J Infect Dis; 2006 Sep; 194 Suppl 1(Suppl 1):S19-26. PubMed ID: 16921467
[No Abstract] [Full Text] [Related]
18. Poly(I)-poly(C12U) but not ribavirin prevents death in a hamster model of Nipah virus infection.
Georges-Courbot MC; Contamin H; Faure C; Loth P; Baize S; Leyssen P; Neyts J; Deubel V
Antimicrob Agents Chemother; 2006 May; 50(5):1768-72. PubMed ID: 16641448
[TBL] [Abstract][Full Text] [Related]
19. Innate immunity for biodefense: a strategy whose time has come.
Amlie-Lefond C; Paz DA; Connelly MP; Huffnagle GB; Whelan NT; Whelan HT
J Allergy Clin Immunol; 2005 Dec; 116(6):1334-42. PubMed ID: 16337468
[TBL] [Abstract][Full Text] [Related]
20. Antivirals and antiviral strategies.
De Clercq E
Nat Rev Microbiol; 2004 Sep; 2(9):704-20. PubMed ID: 15372081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
